Marco Ruella

Targets

• CD19 3
• CCR5 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

  Blood, Aug 2026

• Publication

  Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

  Nature medicine, Aug 2026

• Publication

  Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.

  Nature communications, May 2026

• Publication

  Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup.

  Nature, Apr 2026

• Publication

  Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

  Science translational medicine, Feb 2026

• Publication

  CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

  Nature medicine, Jan 2026

• Publication

  CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access.

  Blood reviews, Dec 2025

• Publication

  Outcomes of relapse after teclistamab therapy in multiple myeloma.

  Blood cancer journal, Nov 2025

Affiliations

• University of Pennsylvania
• Abramson Cancer Center

Co-authors

• CJCarl H JuneHow are we linked?
• MMMarcela V MausHow are we linked?
• SSSandra Susanibar-AdaniyaHow are we linked?

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.